We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Kraig Biocraft Laboratories Inc (QB) | USOTC:KBLB | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00175 | 1.97% | 0.09075 | 0.082 | 0.0909 | 0.092 | 0.08635 | 0.0895 | 302,283 | 21:00:07 |
Wyoming
|
|
|
|
83-0458707
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
None
|
|
-
|
|
-
|
●
To re-elect the sole director to the Company
’
s board of directors (the
“
Board
”
),
with such director to serve until the 2020 annual meeting of
shareholders.
|
Election of Director
|
For
|
Against
|
Abstain
|
Kim
Thompson
|
811,596,328
|
7,378,539
|
2,705,900
|
There
were 0 abstentions and 0 broker non-votes.
|
|
The
Company is currently working to add at least 3 additional
independent directors to meet the listing requirements for a
national securities exchange. As per the Company’s bylaws,
these additional directors will be appointed by the board and we
will file another Current Report on Form 8-K to disclose the
appointment of any director. During the meeting, shareholders voted
to approve an uplisting of the Company to a national securities
exchange.
|
|
For
|
Against
|
Abstain
|
773,069,034
|
41,055,353
|
7,556,380
|
There
were 0 abstentions and 0 broker non-votes.
|
●
To approve a reverse stock split of the Company’s issued and
outstanding Class A Stock by a ratio of not less than one-for-ten
and not more than one-for-forty (the “Reverse Split”)
at any time prior to July 23, 2020, with the exact ratios to be set
at a whole number within this range, as determined by our board of
directors in its sole discretion and approve and adopt the Articles
of Amendment to affect same (the “Reverse Split
Proposal”)
|
For
|
Against
|
Abstain
|
747,106,008
|
62,150,559
|
12,424,200
|
There
were 0 abstentions and 0 broker non-votes.
|
Approval
of this vote does not require the Company to complete a reverse
split, this vote simply authorizes the board to issue a reverse if
the Board believes it in the best interest of the Company. The
Company’s board anticipates that, if exercised, a reverse
split would be completed to meet the listing requirements of an
uplist to a national securities exchange, or to allow investment
from larger institutional investors currently prohibited from
investing in the Company. The Company will file another Current
Report on Form 8-K to disclose such events, should they
occur.
|
●
To approve, by non-binding, advisory vote, the uplisting of
the Company’s Class A Class A Stock, no par value (the
“Class A Stock”) from the OTCQB
to a national securities exchange
, such as
NASDAQ or NYSE:American
|
For
|
Against
|
Abstain
|
810,056,789
|
7,395,793
|
4,228,185
|
There
were 0 abstentions and 0 broker non-votes.
|
As
described at the shareholder meeting, the Company is working toward
a move from the OTC and onto a national exchange. The Company
believes that listing on a nation exchange will provide; additional
liquidity for shareholders, allow for institutional investment, and
open up additional pathways to finance the commercialization of its
spider silk materials. The Company will file another Current Report
on Form 8-K to disclose such events, should they
occur.
|
●To
transact such other business as may properly come before the
Meeting or any adjournment or postponement
thereof
|
For
|
Against
|
Abstain
|
790,198,556
|
6,386,974
|
25,095,236
|
|
There
were 0 abstentions and 0 broker non-votes.
|
||
|
|
●To
direct the chairman of the meeting to adjourn the meeting to a
later date or dates, if necessary, to permit further solicitation
and vote of proxies if, based upon the tabulated vote at the time
of the annual meeting, there are not sufficient votes to approve
any of the foregoing proposals.
|
For
|
Against
|
Abstain
|
787,737,024
|
16,753,142
|
16,464,601
|
There
were 0 abstentions and 0 broker non-votes.
|
|
Kraig Biocraft laboratories, Inc.
|
|
|
|
|
|
By:
|
/s/ Kim
Thompson
|
|
|
Kim
Thompson
|
|
|
President,
Chief Executive Officer and Chief Financial Officer
|
1 Year Kraig Biocraft Laborator... (QB) Chart |
1 Month Kraig Biocraft Laborator... (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions